CTOs on the Move

XTL Biopharmaceuticals

www.xtlbio.com

 
XTL Biopharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.xtlbio.com
  • 750 Lexington Ave Fl 20
    New York, NY USA 10022
  • Phone: 212.531.5960

Executives

Name Title Contact Details

Similar Companies

Seres Therapeutics

Seres Therapeutics is a clinical stage biotherapeutic company focused on discovering and developing Ecobioticâ„¢ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. Founded by Flagship VentureLabs, Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span infectious, metabolic, and inflammatory diseases.

Incyte

Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines that will meet serious unmet medical needs in oncology and other diseases. Incyte is a company driven by innovation, and we believe that investment in cutting-edge science and the rigorous pursuit of R&D excellence can translate into new medicines for serious unmet medical needs that positively impact patients` lives. Incyte has a diverse and growing portfolio of first-in-class and best-in-class product candidates, including both small and large molecules. Incyte is headquartered in Wilmington, Delaware with operations in 10 European countries and Japan. Our more than 1,000 employees are led by distinguished executives with proven records of success. We are proud to have been recognized by Forbes as one of the World`s Most Innovative Companies for each of the past three years.

Anjarium Biosciences

Pioneering the next generation of non-viral gene therapy - by tackling more diseases, more precisely and in a more personalized way.

RayzeBio

RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020

Ferre Institute

Ferre Institute is a Binghamton, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.